Among the animal models of tuberculosis (TB), the non-human primates, particularly rhesus macaques (Macaca fascicularis) and cynomolgus macaques (Macaca mulatta), share the greatest anatomical and physiological similarities with humans. Macaques are highly susceptible to Mycobacterium tuberculosis infection and manifest the complete spectrum of clinical and pathological manifestations of TB as seen in humans. Therefore, the macaque models have been used extensively for investigating the pathogenesis of M. tuberculosis infection and for preclinical testing of drugs and vaccines against TB. This review focuses on published major studies that exemplify how the rhesus and cynomolgus macaques have enhanced and may continue to advance global efforts in TB research.
INTRODUCTION
Among the animal models of tuberculosis (TB), the nonhuman primates (NHPs), particularly rhesus macaques (Macaca fascicularis) and cynomolgus macaques (Macaca mulatta), share the greatest anatomical and physiological similarities with humans. Macaques are highly susceptible to Mycobacterium tuberculosis infection and manifest the complete spectrum of clinical and pathological manifestations of TB as seen in humans. Therefore, the macaque models have been used extensively for investigating the pathogenesis of M. tuberculosis infection and for preclinical testing of drugs and vaccines against TB. This review focuses on published major studies that exemplify how the rhesus and cynomolgus macaques have enhanced and may continue to advance global efforts in TB research.
Validation of Macaques in TB Research
The macaques have proven to be a suitable model for understanding human TB, because they exhibit remark-able similarities to humans in virtually every aspect of their anatomy and physiology (1) (2) (3) . As such, macaques respond likewise to many human immunologic, pathological, and drug agents, providing a tremendous advantage over other animal models (4, 5) . The macaques appear naturally susceptible to M. tuberculosis infection and can display all features of human TB disease, ranging from acute and active infection to asymptomatic and latent infection. The literature shows that macaques and humans share extensive clinical manifestations of TB, including pulmonary and extrapulmonary signs and symptoms (4, 5) . Researchers can monitor the disease course of M. tuberculosis infection in macaques by measuring nearly identical parameters as tested in humans, ranging from skin and blood tests to radiographic imaging and body fluid samples ( Table 1 ). In addition, multidrug chemotherapy for TB provides effective treatment in both humans and macaques (6, 7) . Furthermore, similarly as in humans, bacillus Calmette-Guérin (BCG) vaccination exhibits variable efficacy in macaques of even the same species (8) (9) (10) . Table 1 outlines the similarities and differences in M. tuberculosis infection between humans and the rhesus macaques (RMs) and cynomolgus macaques (CMs).
Historical Use of Macaque Models
The use of macaque models for TB studies traces back to published literature from the 1960s. This "Golden Age" of TB research using macaque models through the 1970s generated valuable data on the evolving BCG vaccine (11) , as well as one report on the TB drug efficacy of ethambutol and isoniazid (7) . The majority of these early studies focused on the BCG-induced immune reactions and vaccine efficacy (12) (13) (14) (15) (16) (17) (18) . All pertinent studies published during this era used Indian RM models, which underwent intrabronchial, intratracheal, or aerosol infection with M. tuberculosis. The estimated mycobacterial retention rate in mammalian lungs after aerosol exposure had derived from prior animal models, includ-ing macaques exposed to anthrax spores, as well as guinea pigs and mice infected with M. tuberculosis (19) . Figure 1 recaps the major published articles of macaque models with experimental M. tuberculosis infection during this time period (7, (12) (13) (14) (15) (16) (17) (18) .
Nearly 2 decades after the Golden Age, another study using macaques experimentally infected with M. tuberculosis was published (20) . This large research gap in using macaque models for TB studies could be due to several factors, including the high maintenance costs and necessary space and equipment for biocontainment to properly conduct such experiments (5) . Additionally, the limited animal availability, handling difficulties, and adverse public opinions have discouraged TB research with NHPs. However, with greater research funding and the emergence of compatible reagents for macaques, further investigations on M. tuberculosis infection using 
The majority of macaques, particularly the rhesus species, develop acute or active TB after artificial infection, whereas 90% of infected humans have latent TB. Chronic infection is defined as persistent signs of active disease, radiographic involvement, or culture positivity. Although the PPD and OT skin tests are used in both humans and macaques, these diagnostic examinations are less reliable in macaques than in humans (72) . Also, macaques exhibit a more random than apical distribution of pulmonary cavities. BAL, bronchoalveolar lavage; CBC, complete blood count; CRP, C-reactive protein; CT, computed tomography; ELISA, enzyme-linked immunosorbent assay; ELISpot, enzyme-linked immunosorbent spot assay; ESR, erythrocyte sedimentation rate; LT, lymphocyte transformation; MRI, magnetic resonance imaging; PPD, purified protein derivative; PET, positron emission tomography; rBCG, recombinant bacillus Calmette-Guérin; SIV, simian immunodeficiency virus; TB, tuberculosis. (+) indicates a present finding or functional modality; (-) means an absent finding or unused modality; (+/-) represents a variable finding; (%) refers to the global percentage infected with M. tuberculosis.
NHP models had regained momentum (4) . Especially amid the expansion of the National Primate Research Centers (NPRCs), TB investigators revisited the macaque model of experimental M. tuberculosis inoculation with a renewed enthusiasm. A series of proceeding investigations dedicated their macaque research to assessing novel TB vaccines and drugs, as well as understanding the pathogenesis of M. tuberculosis infection and reactivation. Figure 2 abridges the RM (8, and CM (4, 10, 20, 37, 38, (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) models of experimental M. tuberculosis infection after the Golden Age, from 1996 to 2016.
Rhesus macaques of Indian origin have often been used as NHP models because they are the primary species provided by the breeding facilities in the United States. However, at least five studies have been reported as using Chinese RM in Wuhan, China (29, 30) , Solna, Sweden (23, 24) , and Rijswijk, the Netherlands (25) . So far, within the scientific literature illustrating macaque models of M. tuberculosis infection, the routes of inoculation have included intrabronchial instillation, as well as intratracheal, aerosol, and intranasal infection. More recently, RM infected with M. tuberculosis via aerosol or intrabronchial instillation have shown similar TB disease outcomes regardless of variations in pulmonary pathology (41) . Although zoonotic TB outbreaks have revealed horizontal transmission of M. tuberculosis, an experimental macaque model of natural M. tuberculosis infection has not been reported. Tables 2 to 4 state the route, dose, and M. tuberculosis strain of infection in each study design along with the major findings of the listed articles. 
A COMPARISON OF RHESUS AND CYNOMOLGUS MACAQUE MODELS OF TB
Both RM and CM models have served to evaluate the efficacy of TB vaccines and drugs, as well as improve our understanding of the immunopathogenesis of M. tuberculosis infection and reactivation. However, the two species have differences worth noting. For example, one investigation revealed that BCG provides greater protective efficacy in CM than in RM against M. tuberculosis infection (37) . Later investigations exploring ultra-low-dose aerosol challenge and stereological techniques for measuring bacterial burden showed that RMs are more susceptible than CMs are to M. tuberculosis infection (59, 60) . As a result, RMs are more often used for the study of active TB, whereas CMs provide better models of latent or chronic TB (4) . Depending on the route and dose of M. tuberculosis infection, as well as the M. tuberculosis strain of inoculum, either CMs or RMs can develop acute, chronic, or latent TB. Therefore, several research endeavors have employed both species for developing and determining the efficacy of TB-screening immunoassays (61-64) ( Table 2 ).
Rhesus Macaques
The RMs have been used extensively to study TB ( Table  3 ). The early investigations during the Golden Age (16) (17) (18) (19) (20) specifically showed that M. tuberculosis infection in RMs progresses rapidly within 8 to 9 weeks after aerosol inhalation of the attenuated H37Rv strain at low doses of up to 62 CFU. In 2004, the Tulane NPRC established a model of asymptomatic, or latent, M. tuberculosis infection of RMs (21) . The investigators revealed that the RMs are a good model for not only active TB, but also asymptomatic TB, using lower doses (30 CFU) of H37Rv strain. In addition to RMs of Indian origin, Chinese RMs could also be used as a viable model of acute TB (29) . Chinese RMs are highly susceptible to M. tuberculosis infection and develop active TB regardless of the dose of H37Rv strain used (29) . In an attempt to improve the methods to monitor the progression of TB disease, Helke et al. (22) from the Oregon NPRC showed that using high-resolution radiographic and fine immunologic studies can help define the disease status in RMs as in humans. Namely, computed tomography evaluation and M. tuberculosis-specific T cell frequencies measured by enzyme-linked immunosorbent spot (ELISpot) assays correlated tightly with the bacterial burden and severity of disease (22) .
Cynomolgus Macaques
In addition to the RMs, the CMs have contributed as animal models in the study of TB (Table 4) of infection closely resembled the pathological and clinical findings of TB in humans, as evidenced by the standard laboratory examinations (4) ( Table 1) . Many of the proceeding publications on CM models of M. tuberculosis infection were similarly published by researchers at the University of Pittsburgh (45-48, 50, 54, 55) . Hence, CM models have more recently been used for evaluating drugs and vaccines against TB (37, 44, 50) .
UNIQUE MACAQUE MODELS OF TB Macaque Models for TB Vaccine Evaluation
Using the RM model, researchers from the Swedish Institute of Infectious Disease Control strived to amplify and extend immune protection against M. tuberculosis. They showed that a recombinant BCG (AFRO-1) could induce strong antigen-specific T cell responses when combined with the TB vaccine vector rAD35 (23, 24) . The Biomedical Primate Research Center in Rijswijk, the Netherlands, aimed to develop a model to test TB vaccines before progressing to human clinical trials (25) . By using an RM model inoculated intratracheally with the Erdman strain of M. tuberculosis, the study revealed that prior immunization with the MVA.85-boosted BCG and an attenuated, phoP-deficient TB vaccine provided effective protection against M. tuberculosis infection. A novel aerosol challenge model achieved by Sharpe et al. (26) helped to assess the endpoints for testing the BCG/MVA.85 vaccine. This NHP model used a three-jet Collision nebulizer in addition to the modified Henderson apparatus, as described by Barclay et al. (13) , in a head-out plethysmography chamber. The findings from these studies indicated that the gamma-interferon indices-ELISpot and enzyme-linked immunosorbent assay (ELISA)-do not relate to the protection against TB; only the magnetic resonance imaging readouts offered a reliable correlate, using ex vivo lung samples removed at necropsy (13, 26) . Another way to objectively measure the efficacy of TB vaccines and drugs was later developed by Luciw et al. (32) at the California NPRC. The conclusions drawn from these studies showed that stereological analysis from magnetic resonance imaging could provide quantitative data, revealing a significant correlation between bacterial load and lung granulomas.
CM models were used much later than RM models for testing TB vaccines. Between 2005 and 2012, three studies using CM models evaluated the efficacy of TB Table 2 displays the experimental designs and major conclusions drawn from TB studies using both rhesus and cynomolgus macaques. All studies (37, 60-64) used Indian RM models. a., aerosol; BCG, bacillus Calmette-Guérin; CM, cynomolgus macaques; Erdman, ATCC 35801 strain unless indicated as K01 strain; i.b., intrabronchial; IFN-γ, gamma interferon; i.t., intratracheal; MR, magnetic resonance; PPD, purified protein derivative; RM, rhesus macaques; TB, tuberculosis.
b TB vaccine-related study. c Studies (62, 63) also used African green monkeys. d Additional RM/CM/African green monkey groups were inoculated with mycobacteria M. kansaii and M. avium (63) .
vaccines that had been tested previously with smallanimal models, including guinea pigs and mice (42, 43) . The first project evaluated the efficacy of the 72f recombinant BCG vaccine and HASP65 + IL-12/HVJ vaccine (42) , which another team of investigators also tested later in Osaka, Japan (43) . Both research inves-tigations showed that the recombinant BCG vaccines were more effective than BCG alone. Soon after, the multistage vaccine H56 was found to increase the effects of BCG to protect CM against active TB and the reactivation of latent TB (50) . Ultimately, the macaque models have presented the potential to help evaluate Table 3 outlines the study designs and major findings of TB investigations using rhesus macaques. All studies, except for those reported in references 28 to 30 and 33, used Indian rhesus macaques. a., aerosol; BCG, bacillus Calmette-Guérin; ELISA, enzyme-linked immunosorbent assay; ELISpot, enzyme-linked immunosorbent spot assay; Erdman, ATCC35801 strain unless indicated as K01 strain; i.b., intrabronchial; i.d., intradermal; INF-γ, gamma interferon; i.n., intranasal; NP, the information is not provided in the paper; RM, rhesus macaques; SIV, simian immunodeficiency virus; TB, tuberculosis; TNF-α, tumor necrosis factor alpha. b TB vaccine-related studies. c One subgroup of macaques was coinfected with M. tuberculosis and SIV.
preventative methods and interventions before reaching human clinical trials, particularly for TB vaccines (65) . Table 5 provides further details on the vaccine dosages and routes of inoculation used in these studies.
Macaque Models for TB Drug Evaluation
Another recent investigation of experimental M. tuberculosis infection in a CM model also came from the University of Pittsburgh School of Medicine (54, 55) . The objective was to determine potential alternative markers for evaluating the efficacy of TB drugs. The studies compared the overall metabolic and radiographic changes, as well as the variations within individual granulomas, in CMs infected with M. tuberculosis. Results from the studies revealed that TB granulomas evolve and resolve independently within a single host and that individual lesions respond variably to different drugs (54) . Furthermore, the clinical findings concluded that the overall positron emission tomography (PET) and computed tomography (CT) signals could be used as prognostic markers to predict successful TB drug therapies. However, the overall metabolic and radiographic changes were nonspecific indicators of metabolic activity, measured from 18 F-fluorodeoxyglucose-radiolabeled glucose in PET/CT imaging data (54) .
Macaque Models for the Study of TB Pathogenesis
By gaining a better understanding of the pathogenesis of M. tuberculosis infection and reactivation of latent TB, researchers can further develop and improve treatment strategies. As such, investigators at the Tulane NPRC profiled the TB granuloma transcriptome in an RM model to identify key immune signaling pathways that are activated during M. tuberculosis infection (27) . Previously, scientists from the Chicago Center for Bio-medical Research characterized gene networks in RMs after only BCG vaccination/infection (66) . Mechanistic studies of M. tuberculosis pathogenesis defined more specific factors employed by M. tuberculosis to successfully infect and persist in mammalian lungs (28) . The identification of a potential therapeutic target sparked from the discovery of the M. tuberculosis stress response factor sigH as an important player in the growth/ replication of M. tuberculosis (33, 34) . Lin et al. (45) characterized the clinical manifestations of TB disease within the three stages: latent, activechronic, and rapidly progressive TB. The results of these studies showed that at necropsy, the CMs with active TB had more CD4+ and CD8+ T cells in the lungs and more gamma-interferon from peripheral blood mononuclear cells, bronchoalveolar lavage, and mediastinal lymph nodes than CMs with latent TB (45) . The same research group also showed that tumor necrosis factor neutralization resulted in disseminated disease in both acute and latent TB with normal granulomatous structures (46) . Another CM study examined the role of CD4+ regulatory T cells in active TB, which occurred in response to increased inflammation rather than acting as a causative factor in the progression to active disease (47) .
The pathological hallmark of M. tuberculosis infection of lung tissue is granuloma formation (67) . In light of the discovery that TB granulomas change uniquely Table 5 highlights novel TB vaccine models that used macaques from 2008 through 2014. In all vaccine studies listed, the novel inoculum was more efficacious than BCG alone. Parameters used to determine greater vaccine efficacy compared with BCG alone included a local increase in CD8 + cytolytic T cells, reduced expression of the M. tuberculosis-specific antigen, and prolonged survival after the challenge. Other considerations involved increased induction of specific IFN-γ responses, reduced pathology and chest X-ray scores, and decreased average lung bacterial counts upon infectious challenge. Reduction in C-reactive protein levels, body weight loss, and decrease of erythrocyteassociated hematologic parameters as markers of inflammatory infection were also taken into account. a., aerosol; AFRO-1, a recombinant BCG expressing perfringolysin and overexpressing M. tuberculosis antigens Ag85A, Ag85B, and TB10.4; BCG, bacillus Calmette-Guérin (Tokyo or Danish strain 1331); CM, cynomolgus macaques; HSP65, mycobacterial heat shock protein; HVJ, hemagglutinating virus of Japan liposome; i.b., intrabronchial; i.d., intradermal; IL-12, interleukin-12; i.m., intramuscular; i.t., intratracheal; mc 2 6020 (H37Rv lysA panCD) and mc 2 within a host (54) , the latest published investigation by Lin et al. (55) aimed to define how these structures vary between CMs with latent and active TB. Interestingly, the sterilization of the granulomas occurred in both stages of TB, regardless of the differential killing of bacteria within a single host (55) . Moreover, TB vaccine-related studies have exposed possible genetic mechanisms of host resistance to M. tuberculosis after immunization (56), as well as immunosuppressant mechanisms of M. tuberculosis virulence (57) . While adding insight into the molecular and pathological pathways of TB progression, these findings may also help to evaluate the disease status as well as incentivize the development of novel therapeutic targets. For example, recent studies (58) show that the dynamics of NF-κB signaling in TB granulomas is a viable therapeutic target to promote macrophage polarization early during infection and to improve outcome. Further evidence of the DosR regulon as a modulator of host T cell responses against M. tuberculosis, allowing mycobacterial persistence (40) , may similarly help develop potential therapeutic targets.
M. tuberculosis/Simian Immunodeficiency Virus Coinfection Macaque Models
Macaques also serve as an excellent model of coinfection with simian immunodeficiency virus (SIV), the counterpart of HIV, which is of importance to understand TB latency and reactivation (31, 68) . Upon inoculation with high-dose BCG (31, 69, 70) , low-dose Erdman strain (48) , or CDC1551 clinical isolate (39) , latently infected RMs and CMs had reactivated TB when coinfected with SIV. Pathogenic SIV-BCG interactions facilitated the development of TB-like disease (70) , while antiretroviral agents restored M. tuberculosis-specific T cell immune responses (31) . The reactivation of latent TB in CM infected with SIV was associated with early T cell depletion and not the virus load (48) . A recent report by Guo et al. (68) showed that SIV infection facilitated M. tuberculosis dissemination in coinfected RMs. The researchers demonstrated that SIV-M. tuberculosiscoinfected animals had significantly lower levels of TB-specific biomarkers, gamma interferon (IFN-γ) and interleukin-22 (IL-22), than monoinfected animals. Another particularly innovative RM model of TB was established at the Southwest NPRC (35) . The purpose of this study was to institute an NHP model for pediatric TB/HIV coinfection. Newborn macaques were infected with M. tuberculosis Erdman strain intrabronchially or via the aerosol route, using an ultrasonic nebulizer specifically adapted for the newborn macaque nose. Investigators confirmed M. tuberculosis infection by various methods, including chest X rays, ELISpot, bronchoalveolar and gastric lavages, and necropsy. Because people with HIV/AIDS carry a high risk of M. tuberculosis infection and disease severity, it is clinically significant to have an NHP model that mimics coinfection. Understanding the pathogenesis of M. tuberculosis/SIV coinfection in macaque models can lead to better management and control of the human TB epidemic.
KEY POINTS AND FUTURE RESEARCH STRATEGIES
Overall, the literature on macaque models of TB has shared four important issues and opportunities for improvement. First, scientists must address the biosafety requirements, cost of equipment and maintenance, and animal availability when considering the use of NHP models in TB research. One alternative is to experiment with smaller genera and species of NHPs that still recapitulate human TB, such as the common marmoset (Callithrix jacchus) model. The marmosets' much higher susceptibility to M. tuberculosis infection and aggressive TB disease progression compared with other NHPs, however, may limit the smaller model's use in long-term studies of immunological response or detecting subtle differences in the virulence of mutant M. tuberculosis strains (71) . Second, the reviewed literature shows that different animal species, individually and as a whole, respond differently when exposed to M. tuberculosis in terms of immunopathogenesis of the TB disease (38, 64) ( Table 2) . Therefore, investigators must define the purpose of the study for the appropriate selection of NHP species. Third, the strain of M. tuberculosis used for inoculation can significantly impact the disease outcome. Instead of employing merely laboratory-adopted Erdman or H37Rv strains, study designs should include clinical isolates of M. tuberculosis. Although this approach may introduce more variability into the NHP studies of TB while making studies performed at different sites more difficult to compare, the findings would likely further mimic human TB disease and add valuable knowledge for the clinical situation. Last, most of the macaque studies so far have shown only acute TB, which is much less prevalent than latent TB in humans. Hence, it is necessary to establish clinically more relevant NHP models that resemble human passive airway transmission. By creating an NHP model of natural M. tuberculosis infection under experimental conditions, researchers would be able to test novel and current TB vaccines/drugs for protection against M. tuberculosis infection.
CONCLUDING REMARKS
The NHP models have served as a valuable tool in TB research over the past several decades. As illustrated in the literature, the CM and RM TB models have clinically revealed similar manifestations of TB disease or latency through multiple diagnostic and prognostic parameters. Even the variability in immune responses to M. tuberculosis infection imitates the diverse human host reactions to the pathogen (36) . Although some studies on TB vaccine evaluation have been conducted by using experimentally infected macaques, the majority of these studies hardly showed the reduction of TB disease progression by BCG-based vaccines. Therefore, a pressing need prevails to establish NHP models that can demonstrate BCGmediated protection against M. tuberculosis infection besides TB disease progression. Even with this shortcoming, however, NHP models that broadly recapitulate many aspects of human TB disease have significant advantages over other (lower vertebrate) animals. Especially in the realm of translational research, the preclinical usage of NHP models for advancing treatments and prevention of M. tuberculosis infection is noteworthy.
GLOSSARY
Cynomolgus macaque (CM) Macaca fascicularis, also called long-tailed macaques, a species of Old World monkeys native to Southeast Asia. CDC 1551 A clinical isolate of M. tuberculosis, exhibiting a similar degree of virulence as the Erdman strain. Erdman strain A virulent subset of M. tuberculosis existing in two forms, including the laboratory ATCC35801 and the clinically isolated K01 strains; most commonly used to study acute tuberculosis. H37Rv An attenuated laboratory strain of M. tuberculosis typically used to study latent infection. Modified Henderson apparatus A device for studying the infectivity and virulence of microorganisms in small air droplets; the three components include a continuous aerosol-generating unit (Collision spray), exposure unit, and sampling unit. Rhesus macaque (RM) Macaca mulatta, a species of Old World monkeys native to Asia; RMs of Indian origin are the most frequently used RM species in tuberculosis research.
